| 242P |
LIPID PROFILE CHANGES IN 245 PATIENTS ON LOPINAVIR/RITONAVIR (LPV/r) AND
THE RESPONSE OF 45 OF THOSE PATIENTS TO LIPID-LOWERING AGENTS (LLAS)
M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew,
G Rubin, K Gough, S Walmsley
University of Toronto, Toronto, Ontario
Objectives: To determine the extent of lipid change after starting
LPV/r and the response to LLAs.
Method: A retrospective cohort study of pts with baseline lipid values
without regards to fasting enrolled in the LPV/r EAP was done. After the initiation
of LPV/r, mean lipids were evaluated at two time periods: 1 M and 6 M(±3 M).
An analysis was done of pts placed on LLAs after starting LPV/r.
Results: Of the 245 patients, 81.8% were on a PI, 40.1% were on an NNRTI
and 33.3% were on both and 29.0% were on a LLA before starting LPV/r. The mean
duration of F/U was 6.1M. The baseline values were not significantly different
for patients on a PI or on a LLA before LPV/r.
|
45 pts were started on a LLA after LPV/r. 53.3% were started on a fibrate,
20.0% on a statin and 26.7% on both. Their mean baseline lipids were: 7.58 for
TC, 9.30 for TG, 0.89 for HDL and 3.63 for LDL. 28 patients had F/U. The mean
lipid change after the LLA was –1.72 for TC (p=0.01), –5.41 for TG (p=0.01),
+0.10 for HDL (p=0.20) and –0.46 for LDL (p=0.25). The proportion with grade
3-4 TG in the group with F/U data was 60.7% at baseline and 21.4% after the
LLA (p=0.02).
Conclusions: TC, TG and HDL increased and LDL decreased after starting
LPV/r. The majority of lipid changes occur by the 1st month after LPV/r. LLA
were effective at decreasing TC and TG.